BR112016002570A2 - alvos moleculares para o tratamento de feridas, em particular, feridas crônicas - Google Patents

alvos moleculares para o tratamento de feridas, em particular, feridas crônicas

Info

Publication number
BR112016002570A2
BR112016002570A2 BR112016002570A BR112016002570A BR112016002570A2 BR 112016002570 A2 BR112016002570 A2 BR 112016002570A2 BR 112016002570 A BR112016002570 A BR 112016002570A BR 112016002570 A BR112016002570 A BR 112016002570A BR 112016002570 A2 BR112016002570 A2 BR 112016002570A2
Authority
BR
Brazil
Prior art keywords
chronic wounds
wound care
molecular targets
particular chronic
homologues
Prior art date
Application number
BR112016002570A
Other languages
English (en)
Inventor
Spiluttini Hébert Béatrice
Dugast-Darzacq Claire
Noizet Maïté
Darzacq Xavier
Original Assignee
Centre Nat Rech Scient
Ecole Normale Superieure
Inst Nat Sante Rech Med
Univ Paris Diderot Paris 7
Urgo Rech Innovation Et Developpement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Ecole Normale Superieure, Inst Nat Sante Rech Med, Univ Paris Diderot Paris 7, Urgo Rech Innovation Et Developpement filed Critical Centre Nat Rech Scient
Publication of BR112016002570A2 publication Critical patent/BR112016002570A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a um composto terapêutico compreendendo: um agente que inibe a atividade de pelo menos um gene selecionado de entre o grupo consistindo em maf, meox2, six2 e homólogos destes possuindo pelo menos 50% de identidade com os referidos genes e / ou um agente que aumenta a atividade de, pelo menos, um gene selecionado do grupo que consiste em creb5, e2f1, egr2, hic1, irf7, jun, myc, srf, stat4, tcf4, fox 1, gli1, sox9 e homólogos destes possuindo pelo menos 50% de identidade com o referido gene para uso no tratamento de feridas, de preferência, feridas crônicas.
BR112016002570A 2013-08-05 2014-07-30 alvos moleculares para o tratamento de feridas, em particular, feridas crônicas BR112016002570A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/001990 WO2015019125A1 (en) 2013-08-05 2013-08-05 Molecular targets for the treatment of wounds, in particular chronic wounds
PCT/EP2014/066344 WO2015018699A1 (en) 2013-08-05 2014-07-30 Molecular targets for the treatment of wounds, in particular chronic wounds

Publications (1)

Publication Number Publication Date
BR112016002570A2 true BR112016002570A2 (pt) 2017-09-12

Family

ID=49447578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002570A BR112016002570A2 (pt) 2013-08-05 2014-07-30 alvos moleculares para o tratamento de feridas, em particular, feridas crônicas

Country Status (8)

Country Link
US (2) US10071097B2 (pt)
EP (2) EP3354659A3 (pt)
JP (2) JP6473155B2 (pt)
CN (1) CN105829338A (pt)
BR (1) BR112016002570A2 (pt)
CA (1) CA2919600A1 (pt)
ES (1) ES2675579T3 (pt)
WO (2) WO2015019125A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053389A1 (en) * 2015-09-21 2017-03-30 Jeffrey Stern Methods for inhibiting epithelial to mesenchymal transition by inhibition of foxs1
EP3402761B1 (en) * 2016-01-11 2020-03-25 Türkiye Sise Ve Cam Fabrikalari A.S. A low-e coated glass which is resistant to thermal process
CN106868006B (zh) * 2017-03-29 2019-12-17 华中科技大学同济医学院附属协和医院 一种e2f1蛋白可结合dna片段及在e2f1活性检测中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891425A2 (en) * 1996-04-23 1999-01-20 President And Fellows Of Harvard College Methods and compositions for regulating t cell subsets by modulating transcription factor activity
DE10235624A1 (de) * 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
EP1944361A1 (en) * 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
JP5641388B2 (ja) * 2009-05-01 2014-12-17 独立行政法人理化学研究所 創傷治療剤及びそのスクリーニング方法
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物
GB201103898D0 (en) * 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds

Also Published As

Publication number Publication date
CA2919600A1 (en) 2015-02-12
US20190022097A1 (en) 2019-01-24
WO2015018699A1 (en) 2015-02-12
EP3354659A3 (en) 2018-09-12
JP6473155B2 (ja) 2019-02-20
WO2015019125A1 (en) 2015-02-12
US20170281628A1 (en) 2017-10-05
JP2016527290A (ja) 2016-09-08
EP3354659A2 (en) 2018-08-01
US10071097B2 (en) 2018-09-11
JP2019038847A (ja) 2019-03-14
EP3030574A1 (en) 2016-06-15
CN105829338A (zh) 2016-08-03
EP3030574B1 (en) 2018-03-28
ES2675579T3 (es) 2018-07-11

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
EA201991369A1 (ru) Модифицированные направляющие рнк
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
UY38428A (es) Nuevos compuestos antihelmínticos
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112016002524A2 (pt) alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides
CY1121427T1 (el) Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112016002570A2 (pt) alvos moleculares para o tratamento de feridas, em particular, feridas crônicas
RS53457B (en) COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD
BR112015028997A2 (pt) biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac
AR099641A1 (es) OSTEONECTINA (SPARC) COMO BLANCO TERAPÉUTICO PARA EL TRATAMIENTO Y PREVENCIÓN DEL FALLO HEPÁTICO AGUDO, COMPOSICIÓN FARMACEUTICA, CONSTRUCTO GENÉTICO, ARNsi, AGENTE QUE INHIBE LA EXPRESIÓN, USO
CL2009000811A1 (es) Polipeptido con actividad antimicrobiana que comprende una secuencia aminoacidica de al menos un 90% de identidad con la secuencia id no:1 para producir un medicamento para tratar la meningitis; uso de dicho polipeptido para tratar la meningitis.
EA201791442A1 (ru) Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров
BR112015022885A2 (pt) composições de promotor
EA202092991A1 (ru) Модифицированные направляющие рнк, которые используются для редактирования генома
RU2014145911A (ru) Способы воздействия на экспрессию гена BRCA2
RU2014145910A (ru) Способы воздействия на экспрессию гена APOE

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]